P3, N=88, Completed, Cairo University

By establishing specific correlations between biochemical and behavioral parameters, this study provides mechanistic insights into VCR-induced neurotoxicity. It proposes 4-PSQ as a promising therapeutic candidate for preventing or reversing chemotherapy-related cognitive and emotional dysfunctions.

The combination therapy based on the in situ vaccine FOLactis and intravenous PD-1 monoclonal antibody showed a certain degree of anti-tumor effect, and was safe and well tolerated in patients with advanced hepatic malignancies.

P1/2, N=40, Active, not recruiting, ECOG-ACRIN Cancer Research Group | N=74 --> 40 | Trial primary completion date: Dec 2025 --> Jul 2025

A double-J ureteral stent was placed, and systemic therapy with vincristine, actinomycin D, and cyclophosphamide (VAC) was initiated. This case highlights a brisk response of disseminated intratesticular rhabdomyosarcoma to VAC chemotherapy and supports comprehensive staging and response-adapted multidisciplinary management. The complete case-level extraction and full citations are provided in the Supplementary material.

P3, N=808, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Mar 2026

This report describes the case of a 7-year-old child with ALL who developed paronychia following combination chemotherapy with vincristine and daunorubicin...A structured, multistep nursing protocol was implemented, including local disinfection, ethacridine lactate compresses, topical application of recombinant human epidermal growth factor solution and mupirocin ointment, and local oxygen insufflation...This case highlights the importance of early recognition of chemotherapy-induced skin toxicity and the value of standardized stepwise wound management in improving functional outcomes. It provides a practical reference for managing this rare yet severe cutaneous adverse reaction in children and underscores the critical role of specialized nursing in supportive oncology care.

P3, N=118, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2026 | Trial primary completion date: Sep 2027 --> Jun 2026

Chalepensin demonstrates promising antitumor activity against L5178Y-R murine lymphoma, along with a favorable acute toxicity profile. These findings support its potential for further preclinical development and warrant additional studies to elucidate its molecular mechanisms and long-term safety.

P=N/A, N=83, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026

The cytotoxicity and pro-apoptotic effects were significantly attenuated by the ROS scavenger NAC. These findings provide a solid preclinical foundation for the further development of this combination therapy and underscore the importance of the "computational prediction-mechanistic validation" strategy in advancing cancer drug discovery.

P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine